Weekly Digest - October 2024

Weekly Digest - October 2024

23 Oct 2024: Hengrui initiated the phase II clinical study of nectin-4 ADC monotherapy for advanced gynecological tumors

  • Hengrui has initiated a Phase II clinical study of SHR-A2102, an ADC targeting Nectin-4, for the treatment of gynecological malignant tumors
  • This study marks the eighth clinical trial for SHR-A2102, which is also being investigated for other cancers, including advanced urothelial carcinoma, non-small cell lung cancer, and esophageal cancer
  • SHR-A2102 is designed to target Nectin-4, a protein associated with tumor development and poor prognosis, and uses a topoisomerase inhibitor as its payload

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home